chemotherapy

SINGAPORE (June 29): RHB is maintaining its “buy” call on TalkMed Group with a lower target price of 73 cents from $1.03 previously following Wednesday’s news of the eight-month suspension of its CEO, Dr Ang Peng Tiam, starting from July 25.  

SINGAPORE (June 28): Ang Peng Tiam, the executive director and CEO of healthcare company TalkMed Group, has been given an eight-month suspension by the Court of Three Judges on the grounds of professional misconduct.